Ritschl, Valentin
Lackner, Angelika
Boström, Carina
Mosor, Erika
Lehner, Michaela
Omara, Maisa
Ramos, Romualdo
Studenic, Paul
Smolen, Josef Sebastian
Stamm, Tanja Alexandra http://orcid.org/0000-0003-3073-7284
Funding for this research was provided by:
AbbVie (10587 / FA 716D0408)
Article History
Received: 6 June 2018
Accepted: 25 September 2018
First Online: 19 October 2018
Ethics approval and consent to participate
: The ethical committees of each institution approved the study (EK 1082/2015 (Vienna, 2 April 2015) and 27–324 ex 14/15 (Graz, 21 July 2015)). All patients gave written and oral informed consent.
: The present manuscript does not contain any individual person’s data, such as individual details, images, or videos.
: PS has received speaker fees from AbbVie, Lilly, and SOBI, and has provided remunerated expert advice to Lilly and Roche. JSS has received grants for his institution from Abbvie, Lilly, MSD, Pfizer, and Roche and has provided remunerated expert advice to and/or had speaking engagements for Abbvie, Amgen, Astra-Zeneca, Astro, BMS, Boehringer-Ingelheim, Celgene, Celltrion, Chugai, Gilead, Glaxo, ILTOO, Janssen, Lilly, Medimmune, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, and UCB. TAS has received speaker fees from AbbVie, Janssen, MSD, Novartis, and Roche, and grant support from AbbVie. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.